Results 51 to 60 of about 29,411 (265)
Advanced Materials for Biologics Delivery to Brain Tumors
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
CD47 regulates the trafficking of specific coding and noncoding RNAs into extracellular vesicles (EVs), and the RNA contents of CD47+ EVs differ from that of CD63+ EVs released by the same cells.
Sukhbir Kaur +4 more
doaj +1 more source
10PD Assessment of PD-L1 and CD47 expression together with tumor-associated TILs in resectable early stage NSCLC [PDF]
Aim/Background: Solid tumors have been shown to evade host antitumor immunity through upregulation of the immune checkpoint PD-1/PD-L1 pathway. However, CD47, an antiphagocytic ligand expressed on tumor cells, represents another cell surface molecule ...
Schmid, Ralph +8 more
core +1 more source
Cell‐Based Biohybrid Micro/Nanorobots for Biotherapy
This review systematically evaluates cell‐based biohybrid micro/nanorobots (CB‐BMRs), highlighting their cell selection criteria, fabrication strategies, and diverse actuation modes. Furthermore, it surveys the promising therapeutic applications of CB‐BMRs in targeted cancer, thrombosis, and inflammation treatments, while comprehensively discussing ...
Lin Wang +11 more
wiley +1 more source
CD47, a “marker of self”, also referred to as integrin-associated protein (IAP) due to association with integrins such as αVβ3, has been first described by Brown et al. in 1990. As member of the immunoglobulin superfamily it contains one IgV-like domain and five transmembrane regions.
openaire +2 more sources
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin +20 more
wiley +1 more source
Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV
Knowledge of human CNS immune responses to AAV‐based gene therapies remains limited due to the lack of immune‐competent human models. Here, a hiPSC‐derived 3D neuroimmune platform integrating neurospheroids and microglia is established using stirred‐tank bioreactors.
Catarina M. Gomes +14 more
wiley +1 more source
Background Traumatic injury to axons produces breakdown of axons and myelin at the site of the lesion and then further distal to this where Wallerian degeneration develops.
Reichert Fanny +4 more
doaj +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
CD47–SIRPα signaling plays an important role in regulating macrophage and dendritic cell (DC) activation. Here we investigated the role of CD47 expression on donor cells in tolerance induction by combined treatment with donor-specific transfusion (DST ...
Yuantao Wang +4 more
doaj +1 more source

